ORMP
ORAMED PHARMACEUTICALS INC.
NASDAQ · Healthcare · Biotechnology · US
$4.10
+2.50%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$4.07
From 52W high−23.22%
Volume58238.00
Market cap$170.55M
P/E (TTM)1.0x
P/S (TTM)—
Div yield6.10%
Key dataNov 4, 2026
Open
$4.07
From 52W high
−23.22%
Volume
58238.00
Market cap
$170.55M
ValuationView details →
P/E (Fwd)
11.1x
EV/EBITDA
0.8x
P/E (TTM)
1.0x
RSI (14)
41.5
MomentumView details →
1D Return
+2.50%
YTD Return
+43.68%
SummaryUpdated Jun 1, 2026
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a clinical-stage biotechnology company founded in 2002 and headquartered in New York. The company was originally incorporated as Integrated Security Technologies, Inc. before changing its name to Oramed Pharmaceuticals in April 2006 and going public in May 2007. Oramed specializes in developing oral drug delivery systems for medications that traditionally require injection, with a primary focus on creating the world's first commercially viable oral insulin capsule for diabetes treatment.
Similar companies
Latest newsMore news →
Lifeward Ltd. signed a securities purchase agreement to issue up to $11.16 million aggregate principal amount of senior secured convertible notes, with $5.58 million issued at closing on July 6, 2026, and the remainder subject to conditions.121d agoScilex loan was substantially repaid to Oramed Pharmaceuticals.132d ago